Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements Of Cash Flows (Unaudited)

v3.20.2
Consolidated Statements Of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash Flows from Operating Activities:    
Net loss $ (10,687) $ (14,268)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:    
Depreciation and amortization 527 754
Provision for bad debts 1,263 1,243
Provision for sales returns 87  
Amortization of discounts on lines of credit 123 103
Amortization of debt issuance costs 240 130
Change in fair value of warrants (5,850)  
Issuance costs for common stock warrants 1,640  
Earned interest income   2
Stock-based compensation 2,367 1,974
Deferred income taxes   (6)
Changes in operating assets and liabilities:    
Accounts receivable 4,017 1,393
Inventory (1,597) 711
Prepaid expenses and other current assets 430 1,011
Accounts payable and accrued liabilities (3,445) (1,157)
Deferred revenue (562) 36
Net cash and cash equivalents used in operating activities (11,447) (8,074)
Cash Flows from Investing Activities:    
Purchases of property, plant, and equipment (78) (138)
Net cash and cash equivalents used in investing activities (78) (138)
Cash Flows from Financing Activities:    
Proceeds from the issuance of common stock 6,912  
Proceeds from the issuance of Series F Convertible Preferred Stock 2,700  
Proceeds from the issuance of July 2020 Warrants 15,300  
Payments of equity offering costs (1,281) (50)
Payment of July 2020 Warrant issuance costs (1,640)  
Borrowings on other long-term loans 3,140  
Borrowings under term loan   2,500
Principal payment on term loan (700)  
Borrowings on credit facility 3,000  
Repayment of credit facility (3,000)  
Proceeds from the exercise of common stock warrants 46  
Payment of debt issuance costs (75) (38)
Proceeds from exercise of stock options   4
Net cash and cash equivalents provided by financing activities 24,402 2,416
Effect of exchange rate changes 181 (157)
Increase (decrease) in cash, cash equivalents and restricted cash 13,058 (5,953)
Cash, cash equivalents and restricted cash, beginning of period 6,101 8,356
Cash, cash equivalents and restricted cash, end of period 19,159 2,403
Supplemental cash flow disclosure:    
Cash paid for interest 1,438 1,315
Cash paid for income taxes 21 19
Cash paid for operating leases 417 606
Non-accrual for accrual for equity offering costs   191
Non-cash accrual for capital expenditures   4
Non-cash settlement of performance award liability 151 236
Non-cash right-of-use assets obtained in exchange for lease obligation 2,037 824
Deemed dividend on preferred stock 17,378  
Warrants issued in connection with debt instruments $ 67 $ 209